Choroid Plexus Carcinoma Clinical Trial
Official title:
Intra-Arterial (IA) Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma (ACPP) and Choroid Plexus Carcinoma (CPC) Prior to Second-Look Surgery
This study will test the safety and efficacy of intra-arterial chemotherapy in subjects with newly diagnosed, residual, or recurrent atypical choroid plexus papilloma and choroid plexus carcinoma prior to a second surgery. It is believed that intra-arterial chemotherapy will be safe and feasible for this population and will result in decreased tumor size, which may further improve the goals of a second-look surgery.
Status | Recruiting |
Enrollment | 6 |
Est. completion date | December 2026 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Years to 100 Years |
Eligibility | Inclusion Criteria: 1. Subjects with a histologically confirmed diagnosis of ACPP or CPC that is newly diagnosed, residual or recurrent. 2. Subjects must have a Karnofsky or Lansky Performance Score = 60 % assessed within two weeks prior to enrollment. Karnofsky is used for patients = 16 years and Lansky for those < 16. 3. Subjects must have normal organ and marrow function documented within 14 days of enrollment and within 7 days of the start of treatment as noted below: 1. Absolute neutrophil count = 1,000/µL 2. Platelets = 100,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment) 3. Hemoglobin = 8 g/dL (may receive PRBC transfusions) 4. Total bilirubin < 1.5 times upper limit of normal for age 5. AST (SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal for age 6. Creatinine clearance or radioisotope GFR = 70 ml/min/1.73m2 or a serum creatinine WNL for age as determined using the Schwartz formula.36 7. Sodium, Potassium, Calcium and Magnesium < 1.5x institutional ULN 8. Albumin = 3 g/dL 4. Subjects who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to enrollment. 5. Subjects with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment. 6. If the subject has any of the following therapies, must be at least: - 4 weeks post-focal RT (radiation therapy), 3 months post-CSI (craniospinal irradiation) - 4 weeks post-myelosuppressive chemotherapy (if post-nitrosoureas, must have 6 weeks therapy) - 4 weeks post-monoclonal antibodies - 1 week post-targeted therapy 7. If subject has received any previous treatment, all treatment related toxicities should have recovered to < grade 2 8. Subject or parent must sign a written informed consent document according to institutional guidelines. Exclusion Criteria: 1. Females who are pregnant or lactating. 2. Subjects with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) likely to interfere with the study procedures or results. 3. Subjects who are receiving any other anticancer or investigational agents. 4. Subjects with uncontrolled seizures. 5. Subjects receiving enzyme inducing anticonvulsants. 6. Subjects with other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) including heart failure that meets New York Heart Association (NYHA) class II or above. 7. Subjects who have had an allogenic bone marrow transplant < 6 months prior to enrollment or an autologous bone marrow/stem cell transplant < 3 months prior to enrollment. 8. Subjects with multifocal disease or disease that has been disseminated will not be eligible for this study. They will undergo systemic chemotherapy and their disease will be further evaluated prior to be eligible for 2nd look surgery. 9. This study will only enroll subjects with ACPP or CPC and will not enroll subjects with choroid plexus papilloma (CPP). ACPP or CPC subjects with symptomatic hydrocephalus will not be eligible for this study. These subjects will have to be treated for their hydrocephalus and be re-evaluated according to our eligibility criteria in order to be enrolled. |
Country | Name | City | State |
---|---|---|---|
United States | Weill Cornell Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Extent of pathology correlation to tumor vascularity and tumor viability | Determined by comparison of pathology reports and surgical outcomes | Around 7 weeks after intra-arterial chemotherapy | |
Primary | Safety of intra-arterial chemotherapy in subjects with ACPP and CPC, measured by the number of serious adverse events that are reported as at least possible related to the intervention that occur in subjects on the trial | Through study completion, a little over a year for each subject | ||
Secondary | The number of successful angiography procedures, determined by examination of vasculature and assessment of catheter placement | On Day 1 of the trial for each subject | ||
Secondary | The number of patients with a tumor volume reduction response, determined by MRI assessments | Between 4-6 weeks after intra-arterial chemotherapy | ||
Secondary | The proportion of patients with a tumor volume reduction response, determined by MRI assessments | Between 4-6 weeks after intra-arterial chemotherapy | ||
Secondary | The number of patients with a tumor vascularity reduction response, determined by MRI assessments | Between 4-6 weeks after intra-arterial chemotherapy | ||
Secondary | The proportion of patients with a tumor vascularity reduction response, determined by MRI assessments | Between 4-6 weeks after intra-arterial chemotherapy | ||
Secondary | The success of second look surgery determined by measuring the extent of tumor resection | Around 7 weeks after intra-arterial chemotherapy, during second look surgery | ||
Secondary | The success of second look surgery determined by amount of blood loss | Around 7 weeks after intra-arterial chemotherapy, during second look surgery | ||
Secondary | The success of second look surgery determined by percent of blood loss | Around 7 weeks after intra-arterial chemotherapy, during second look surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03638167 -
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03500991 -
HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05934630 -
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
|
||
Withdrawn |
NCT04521946 -
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
|
Phase 1 | |
Recruiting |
NCT04185038 -
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
|
Phase 1 | |
Recruiting |
NCT03050268 -
Familial Investigations of Childhood Cancer Predisposition
|